Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM91KZL)

• Drug Name: SAR445877 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM91KZL

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-15 (IL15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BNZ-1	DM8JQZC	Cutaneous T-cell lymphoma	2B01	Phase 2	[3]
AMG-714	DM1T3KQ	Coeliac disease	DA95	Phase 2	[4]
N-803	DM4ZN8M	Human immunodeficiency virus infection	1C62	Phase 1	[5]
PF-07209960	DM1W90B	Aggressive cancer	2A00-2F9Z	Phase 1	[6]

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[7]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[8]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[7]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[9]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[10]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[11]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[12]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[13]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[14]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-15 (IL15)	TTJFA35	IL15_HUMAN	Not Available	[2]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT05584670) A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Sanofi
• [3] Clinical pipeline report, company report or official report of Bioniz Therapeutics.
• [4] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [5] The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339.
• [6] ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
• [7] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [8] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [9] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [10] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [13] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [14] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)